The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy

FEBS J. 2013 Sep;280(17):4210-29. doi: 10.1111/febs.12295. Epub 2013 May 13.

Abstract

Three adhesion complexes span the sarcolemma and facilitate critical connections between the extracellular matrix and the actin cytoskeleton: the dystrophin- and utrophin-glycoprotein complexes and α7β1 integrin. Loss of individual protein components results in a loss of the entire protein complex and muscular dystrophy. Muscular dystrophy is a progressive, lethal wasting disease characterized by repetitive cycles of myofiber degeneration and regeneration. Protein-replacement therapy offers a promising approach for the treatment of muscular dystrophy. Recently, we demonstrated that sarcospan facilitates protein-protein interactions amongst the adhesion complexes and is an important potential therapeutic target. Here, we review current protein-replacement strategies, discuss the potential benefits of sarcospan expression, and identify important experiments that must be addressed for sarcospan to move to the clinic.

Keywords: Duchenne; dystrophin; integrin; laminin-binding; mdx; muscle; muscular dystrophy; sarcolemma; sarcospan; utrophin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Carrier Proteins / metabolism*
  • Dystrophin / metabolism*
  • Humans
  • Integrins / metabolism*
  • Membrane Proteins / metabolism*
  • Muscular Dystrophies / metabolism
  • Muscular Dystrophies / therapy*
  • Neoplasm Proteins / metabolism*
  • Sarcolemma / metabolism*
  • Signal Transduction
  • Utrophin / metabolism*

Substances

  • Carrier Proteins
  • Dystrophin
  • Integrins
  • Membrane Proteins
  • Neoplasm Proteins
  • SSPN protein, human
  • Utrophin
  • integrin alpha7beta1